|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZBED6 |
Gene summary for ZBED6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZBED6 | Gene ID | 100381270 |
| Gene name | zinc finger BED-type containing 6 | |
| Gene Alias | MGR | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P86452 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100381270 | ZBED6 | C04 | Human | Oral cavity | OSCC | 7.26e-09 | 5.46e-01 | 0.2633 |
| 100381270 | ZBED6 | C21 | Human | Oral cavity | OSCC | 7.21e-21 | 6.05e-01 | 0.2678 |
| 100381270 | ZBED6 | C30 | Human | Oral cavity | OSCC | 7.06e-06 | 4.02e-01 | 0.3055 |
| 100381270 | ZBED6 | C43 | Human | Oral cavity | OSCC | 1.43e-02 | 1.65e-01 | 0.1704 |
| 100381270 | ZBED6 | C46 | Human | Oral cavity | OSCC | 1.08e-09 | 2.81e-01 | 0.1673 |
| 100381270 | ZBED6 | C08 | Human | Oral cavity | OSCC | 1.43e-04 | 2.50e-01 | 0.1919 |
| 100381270 | ZBED6 | LN46 | Human | Oral cavity | OSCC | 7.99e-04 | 1.86e-01 | 0.1666 |
| 100381270 | ZBED6 | SYSMH1 | Human | Oral cavity | OSCC | 3.71e-20 | 4.90e-01 | 0.1127 |
| 100381270 | ZBED6 | SYSMH2 | Human | Oral cavity | OSCC | 5.29e-16 | 5.09e-01 | 0.2326 |
| 100381270 | ZBED6 | SYSMH3 | Human | Oral cavity | OSCC | 1.18e-14 | 4.25e-01 | 0.2442 |
| 100381270 | ZBED6 | SYSMH4 | Human | Oral cavity | OSCC | 2.24e-02 | 1.76e-01 | 0.1226 |
| 100381270 | ZBED6 | SYSMH5 | Human | Oral cavity | OSCC | 2.86e-09 | 3.03e-01 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| GO:00018243 | Oral cavity | OSCC | blastocyst development | 66/7305 | 106/18723 | 1.04e-06 | 1.40e-05 | 66 |
| GO:000974320 | Oral cavity | OSCC | response to carbohydrate | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
| GO:003428420 | Oral cavity | OSCC | response to monosaccharide | 114/7305 | 225/18723 | 2.37e-04 | 1.54e-03 | 114 |
| GO:007133316 | Oral cavity | OSCC | cellular response to glucose stimulus | 79/7305 | 151/18723 | 5.97e-04 | 3.39e-03 | 79 |
| GO:000974619 | Oral cavity | OSCC | response to hexose | 109/7305 | 219/18723 | 7.41e-04 | 4.05e-03 | 109 |
| GO:000167816 | Oral cavity | OSCC | cellular glucose homeostasis | 88/7305 | 172/18723 | 7.74e-04 | 4.22e-03 | 88 |
| GO:007133116 | Oral cavity | OSCC | cellular response to hexose stimulus | 79/7305 | 153/18723 | 9.92e-04 | 5.17e-03 | 79 |
| GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
| GO:000974917 | Oral cavity | OSCC | response to glucose | 105/7305 | 212/18723 | 1.13e-03 | 5.78e-03 | 105 |
| GO:004259316 | Oral cavity | OSCC | glucose homeostasis | 125/7305 | 258/18723 | 1.21e-03 | 6.08e-03 | 125 |
| GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
| GO:007132616 | Oral cavity | OSCC | cellular response to monosaccharide stimulus | 79/7305 | 154/18723 | 1.27e-03 | 6.33e-03 | 79 |
| GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
| GO:003350016 | Oral cavity | OSCC | carbohydrate homeostasis | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
| GO:00611788 | Oral cavity | OSCC | regulation of insulin secretion involved in cellular response to glucose stimulus | 37/7305 | 64/18723 | 1.76e-03 | 8.31e-03 | 37 |
| GO:007132217 | Oral cavity | OSCC | cellular response to carbohydrate stimulus | 82/7305 | 163/18723 | 2.14e-03 | 9.81e-03 | 82 |
| GO:00507089 | Oral cavity | OSCC | regulation of protein secretion | 126/7305 | 268/18723 | 4.41e-03 | 1.79e-02 | 126 |
| GO:00357736 | Oral cavity | OSCC | insulin secretion involved in cellular response to glucose stimulus | 40/7305 | 73/18723 | 4.45e-03 | 1.79e-02 | 40 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZBED6 | SNV | Missense_Mutation | novel | c.138N>C | p.Lys46Asn | p.K46N | P86452 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.952) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZBED6 | SNV | Missense_Mutation | novel | c.1157C>T | p.Ala386Val | p.A386V | P86452 | protein_coding | tolerated(0.4) | benign(0) | TCGA-E2-A570-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| ZBED6 | SNV | Missense_Mutation | novel | c.47G>A | p.Gly16Asp | p.G16D | P86452 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZBED6 | SNV | Missense_Mutation | c.2654N>C | p.Leu885Ser | p.L885S | P86452 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZBED6 | SNV | Missense_Mutation | c.1136N>G | p.Ser379Cys | p.S379C | P86452 | protein_coding | tolerated(0.06) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZBED6 | SNV | Missense_Mutation | novel | c.1419N>C | p.Glu473Asp | p.E473D | P86452 | protein_coding | deleterious(0.04) | possibly_damaging(0.903) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZBED6 | SNV | Missense_Mutation | novel | c.368N>C | p.Ile123Thr | p.I123T | P86452 | protein_coding | deleterious(0.01) | possibly_damaging(0.846) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZBED6 | SNV | Missense_Mutation | novel | c.710N>A | p.Ser237Tyr | p.S237Y | P86452 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.963) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZBED6 | SNV | Missense_Mutation | novel | c.472N>A | p.Val158Ile | p.V158I | P86452 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
| ZBED6 | SNV | Missense_Mutation | rs749876751 | c.2534G>A | p.Ser845Asn | p.S845N | P86452 | protein_coding | tolerated(0.18) | benign(0.014) | TCGA-AX-A3FX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |